Trial Profile

A multicenter, randomized, open-label, active-controlled phase II study evaluating the efficacy and safety of IBI110 in combination with sintilimab and chemotherapy in patients with advanced squamous non-small cell lung cancer (sqNSCLC).

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Feb 2026 New trial record
27 Jan 2026 Primary endpoint (safety) has not been met.
27 Jan 2026 Primary endpoint (progression-free survival (PFS)) has not been met, according to the results published in Cancer Immunology Immunotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com